Nuvig Therapeutics Secures $161M to Advance Autoimmune Therapy NVG-2089 to Phase 2 Trials

Nuvig Therapeutics, a biotechnology company located in Menlo Park, California, focuses on the innovative treatment of autoimmune diseases through an approach that seeks to rebalance immune function rather than suppress it. The company recently raised $161 million in a Series B funding round, supported by prominent investors such as Sanofi Ventures, Bayer, and Bristol Myers Squibb[1][2]. Nuvig's lead therapy, NVG-2089, targets and activates Type II Fc receptors, aiming to address conditions like chronic inflammatory demyelinating polyneuropathy (CIDP) without broadly compromising the immune system. With initial trials confirming its safety and efficacy, NVG-2089 is progressing to phase 2 trials, and the funding will also bolster Nuvig’s early-stage research projects[3].